Online inquiry

IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14850MR)

This product GTTS-WQ14850MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14850MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13756MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ957MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ8069MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ584MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ7104MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ7155MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ15898MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ7036MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab C225
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW